Is there any potential or additive effect of anemia on hepatorenal syndrome?

In the logistic regression analysis, the hemoglobin levels and CTP and MELD scores were statistically significant for an onset of HRS.Conclusion: Anemia may contribute to HRS and deteriorated renal function in patients with HRS because anemic hypoxia can lead to microcirculatory renal ischemia in the kidneys and anemia can also activate sympathetic activity and hyperdynamic circulation in the pathogenesis of HRS

📌 3 Maddede Bu Makale

🎯

Amaç & Hipotez:Background/Aims: Hepatorenal syndrome (HRS) is a severe complication of advanced cirrhosis and is characterized by renal dysfunction and poor survival rates.

📊

Temel Bulgular & Veri:A total of 29 patients with cirrhosis with HRS meeting the HRS diagnostic criteria (9 patients with type 1 HRS and 20 with type 2 HRS) and 37 patients with cirrhosis without HRS were included.

💡

Sonuç & Katkı:In the logistic regression analysis, the hemoglobin levels and CTP and MELD scores were statistically significant for an onset of HRS.Conclusion: Anemia may contribute to HRS and deteriorated renal function in patients with HRS because anemic hypoxia can lead to microcirculatory renal ischemia in the kidneys and anemia can also activate sympathetic activity and hyperdynamic circulation in the pathogenesis of HRS

🔬Tür:Modelleme & Sayısal Simülasyon

📍Kapsam:Genişletilmiş Akademik Örneklem

⚙️Değişkenler:Alan Parametreleri

Özet

Background/Aims: Hepatorenal syndrome (HRS) is a severe complication of advanced cirrhosis and is characterized by renal dysfunction and poor survival rates. Although anemia is a non-rare condition in advanced liver cirrhosis, there is no publication regarding the potential or additive effects of anemia on HRS and renal dysfunction in patients with cirrhosis. We investigated whether severe anemia is a precipitant factor for HRS.Materials and Methods: In this prospective study, consecutive patients with cirrhosis with and without renal dysfunction were enrolled. A total of 29 patients with cirrhosis with HRS meeting the HRS diagnostic criteria (9 patients with type 1 HRS and 20 with type 2 HRS) and 37 patients with cirrhosis without HRS were included. The demographic features, laboratory data (particularly anemic parameters), and clinical scores of patients with and without HRS were evaluated.Results: Grades of ascites, Child-Turcotte-Pugh (CTP) scores, and Model of End Stage Liver Disease (MELD) scores were significantly higher in contrast to hemoglobin levels; hematocrit concentrations were significantly lower in patients with type 1 and 2 HRS than in those with non-HRS stable cirrhosis. There was a negative correlation between the hemoglobin-hematocrit and serum creatinine levels. In the logistic regression analysis, the hemoglobin levels and CTP and MELD scores were statistically significant for an onset of HRS.Conclusion: Anemia may contribute to HRS and deteriorated renal function in patients with HRS because anemic hypoxia can lead to microcirculatory renal ischemia in the kidneys and anemia can also activate sympathetic activity and hyperdynamic circulation in the pathogenesis of HRS

🔖

Bu Makaleye Atıf Yap

GÜNGÖR, G., AKYILDIZ, M., KESKİN, M., SOLAK, Y., GAIPOV, A., BIYIK, M., CIFCI, S., ATASEVEN, H., POLAT, H., DEMİR, A. (2016). Is there any potential or additive effect of anemia on hepatorenal syndrome?. Turkish Journal of Gastroenterology, Cilt: 27 - Sayı: 3, 273–278. https://ajindex.com/articles/410235

📄 Tam Metin PDF Okuyucu

Yeni Sekmede Aç ↗

↗Yeni Sekme

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (5)

Fagundes C, Ginès P. Hepatorenal syndrome: a severe, but treat- able, cause of kidney failure in cirrhosis. Am J Kidney Dis 2012; 59: 874-85. [CrossRef] Ginès P, Schrier RW. Renal failure in cirrhosis. N Engl J Med 2009; 361: 1279-90. [CrossRef] Ginès P, Guevara M, Arroyo V, Rodés J. Hepatorenal syndrome. Lancet 2003; 362: 1819-27. [CrossRef] Wadei HM, Mai ML, Ahsan N, Gonwa TA. Hepatorenal syndrome: pathophysiology and management. Clin J Am Soc Nephrol 2006; 1: 1066-79. [CrossRef] Martin PY, Ginès P, Schrier RW. Nitric oxide as a mediator of he- modynamic abnormalities and sodium and water retention in cirrhosis. N Engl J Med 1998; 339: 533-41. [CrossRef] Iwakiri Y. The molecules: mechanisms of arterial vasodilatation observed in the splanchnic and systemic circulation in portal hypertension. J Clin Gastroenterol 2007; 41(Suppl 3): S288-94. [CrossRef] Hua R, Cao H, Wu ZY. Effects of hemoglobin concentration on hyperdynamic circulation associated with portal hypertension. Hepatobiliary Pancreat Dis Int 2006; 5: 215-8.
Cirera I, Elizalde JI, Piqué JM, et al. Anemia worsens hyperdynamic circulation of patients with cirrhosis and portal hypertension. Dig Dis Sci 1997; 42: 1697-702. [CrossRef] Gungor G, Ataseven H, Demir A, et al. Neutrophil Gelatinase- Associated Lipocalin in prediction of mortality in Patients with Hepatorenal Syndrome: a prospective observational study. Liver Int 2014; 34: 49-57. [CrossRef] Schrier RW, Shchekochikhin D, Gines P. Renal failure in cirrhosis: prerenal azotemia, hepatorenal syndrome and acute tubular ne- crosis. Nephrol Dial Transplant 2012a; 27: 2625-8. [CrossRef] Salerno F, Gerbes A, Gines P, Wong F, Arroyo V. Diagnosis, preven- tion and treatment of hepatorenal syndrome in cirrhosis. Gut 2007; 56: 1310-8.
Lang F, Tschernko E, Haussinger D. Hepatic regulation of renal function. Exp Physiol 1992; 77: 663-73. [CrossRef] Lang F, Ottl I, Häussinger D, Deetjen P, Ahloulay M, Bankir L. Renal hemodynamic response to intravenous and oral amino acids in animals. Semin Nephrol 1995; 15: 415-8.
Michielsen PP, Pelckmans PA. Haemodynamic changes in portal hypertension: new insights in the pathogenesis and clinical im- plications. Acta Gastroenterol Belg 1994; 57: 194-205.
Rabelink TJ, Kaasjager KA, Boer P, Stroes EG, Braam B, Koomans HA. Effects of endothelin-1 on renal function in humans: implica- tions for physiology and pathophysiology. Kidney Int 1994; 46: 376-81. [CrossRef] Fukunaga M, Yura T, Badr KF. Stimulatory effect of 8-Epi-PGF